• 1
    Easton DF,Pooley KA,Dunning AM,Pharoah PD,Thompson D,Ballinger DG,Struewing JP,Morrison J,Field H,Luben R,Wareham N,Ahmed S, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 108793.
  • 2
    Garcia-Closas M,Hall P,Nevanlinna H,Pooley KA,Morrison J,Richesson D,Bojesen SE,Nordestgaard BG,Axelsson CK,Arias JI,Milne RL,Ribas G, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008; 4: e1000054.
  • 3
    Ross JS,Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3: 23752.
  • 4
    Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 17346.
  • 5
    Piccart-Gebhart MJ,Procter M,Leyland-Jones B,Goldhirsch A,Untch M,Smith I,Gianni L,Baselga J,Bell R,Jackisch C,Cameron D,Dowsett M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 165972.
  • 6
    Romond EH,Perez EA,Bryant J,Suman VJ,Geyer CE,Jr,Davidson NE,Tan-Chiu E,Martino S,Paik S,Kaufman PA,Swain SM,Pisansky TM, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 167384.
  • 7
    Hollywood DP,Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumor lines. EMBO J 1993; 12: 236975.
  • 8
    Pasleau F,Grooteclaes M,Gol-Winkler R. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 1993; 8: 84954.
  • 9
    Bosher JM,Williams T,Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 1995; 92: 7447.
  • 10
    Scott GK,Chang CH,Erny KM,Xu F,Fredericks WJ,Rauscher FJ,III,Thor AD,Benz CC. Ets regulation of the erbB2 promoter. Oncogene 2000; 19: 6490502.
  • 11
    Vernimmen D,Begon D,Salvador C,Gofflot S,Grooteclaes M,Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 2003; 370: 3239.
  • 12
    Fernandez PL,Jares P,Rey MJ,Campo E,Cardesa A. Cell cycle regulators and their abnormalities in breast cancer. Mol Pathol 1998; 51: 3059.
  • 13
    Alkarain A,Slingerland J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 2004; 6: 1321.
  • 14
    Arnold A,Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005; 23: 421524.
  • 15
    Arykok AT,Onal BU,Han U. Expressions of cyclin D1, p53, bcl-2, and bax in infiltrative ductal carcinoma of the breast: correlations with clinicopathologic characteristics. Breast J 2006; 12: 3912.
  • 16
    Caldon CE,Daly RJ,Sutherland RL,Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2006; 97: 26174.
  • 17
    Colozza M,Azambuja E,Cardoso F,Sotiriou C,Larsimont D,Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 172339.
  • 18
    Hilakivi-Clarke L,Wang C,Kalil M,Riggins R,Pestell RG. Nutritional modulation of the cell cycle and breast cancer. Endocr Relat Cancer 2004; 11: 60322.
  • 19
    Bracken AP,Ciro M,Cocito A,Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci 2004; 29: 40917.
  • 20
    Ma Y,Yuan J,Huang M,Jove R,Cress WD. Regulation of the cyclin D3 promoter by E2F1. J Biol Chem 2003; 278: 167706.
  • 21
    Justenhoven C,Hamann U,Pesch B,Harth V,Rabstein S,Baisch C,Vollmert C,Illig T,Ko YD,Bruning T,Brauch H. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 2004; 13: 205964.
  • 22
    Justenhoven C,Pierl CB,Haas S,Fischer HP,Baisch C,Hamann U,Harth V,Pesch B,Bruning T,Vollmert C,Illig T,Dippon J, et al. The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 2008; 111: 1717.
  • 23
    Justenhoven C,Hamann U,Schubert F,Zapatka M,Pierl CB,Rabstein S,Selinski S,Mueller T,Ickstadt K,Gilbert M,Ko YD,Baisch C, et al. Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 2008; 108: 13749.
  • 24
    Pesch B,Ko Y,Brauch H,Hamann U,Harth V,Rabstein S,Pierl C,Fischer HP,Baisch C,Justenhoven C,Ranft U,Bruning T. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005; 20: 699711.
  • 25
    Vollmert C,Windl O,Xiang W,Rosenberger A,Zerr I,Wichmann HE,Bickeboller H,Illig T,Kretzschmar HA. Significant association of a M129V independent polymorphism in the 5′ UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study. J Med Genet 2006; 43: e53.
  • 26
    Haas S,Pierl C,Harth V,Pesch B,Rabstein S,Bruning T,Ko Y,Hamann U,Justenhoven C,Brauch H,Fischer HP. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer 2006; 119: 178591.
  • 27
    Goldhirsch A,Wood WC,Gelber RD,Coates AS,Thurlimann B,Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 335765.
  • 28
    Driver KE,Song H,Lesueur F,Ahmed S,Barbosa-Morais NL,Tyrer JP,Ponder BA,Easton DF,Pharoah PD,Dunning AM. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 2008; 29: 33341.
  • 29
    Forsti A,Angelini S,Festa F,Sanyal S,Zhang Z,Grzybowska E,Pamula J,Pekala W,Zientek H,Hemminki K,Kumar R. Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004; 11: 91722.
  • 30
    Grieu F,Malaney S,Ward R,Joseph D,Iacopetta B. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 2003; 23: 42579.
  • 31
    Krippl P,Langsenlehner U,Renner W,Yazdani-Biuki B,Wolf G,Wascher TC,Paulweber B,Weitzer W,Leithner A,Samonigg H. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 2003; 82: 1658.
  • 32
    Naidu R,Yip CH,Taib NA. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma 2008; 55: 8795.
  • 33
    Onay UV,Aaltonen K,Briollais L,Knight JA,Pabalan N,Kilpivaara O,Andrulis IL,Blomqvist C,Nevanlinna H,Ozcelik H. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 2008; 8: 6.
  • 34
    Yoon SO,Shin S,Mercurio AM. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. Cancer Res 2006; 66: 628895.
  • 35
    Kuwada SK,Kuang J,Li X. Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells. J Biol Chem 2005; 280: 1902735.
  • 36
    Xu W,Marcu M,Yuan X,Mimnaugh E,Patterson C,Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 2002; 99: 1284752.
  • 37
    Zhou P,Fernandes N,Dodge IL,Reddi AL,Rao N,Safran H,DiPetrillo TA,Wazer DE,Band V,Band H. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003; 278: 1382937.
  • 38
    Malumbres M,Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 22231.
  • 39
    Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006; 24: 139.
  • 40
    Betticher DC,Thatcher N,Altermatt HJ,Hoban P,Ryder WD,Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 100511.
  • 41
    Coqueret O. Linking cyclins to transcriptional control. Gene 2002; 299: 3555.
  • 42
    Liu W,Sun M,Jiang J,Shen X,Sun Q,Liu W,Shen H,Gu J. Cyclin D3 interacts with human activating transcription factor 5 and potentiates its transcription activity. Biochem Biophys Res Commun 2004; 321: 95460.